Efficacy of the New Viviscal Professional Strength Oral Supplement in Females With Thinning Hair

NCT02302053 | Completed

• 1 other identifier: ADHT-0213
• Study Type: interventional
• Target: 40
• Locations: 0 countries
• Sites: N/A

Brief Summary

The New Viviscal Professional Strength is an oral food supplement specifically designed to promote hair growth for women suffering from temporary thinning hair. It does not contain hormones, drugs or industry by-products. Viviscal has been marketed in Europe for over 15 years. The purpose of this clinical research study is to evaluate certain physiological effects of Viviscal compared to placebo in forty (40) female subjects, ages 21-75 years of age with self-perceived thinning hair associated with poor diet, stress, hormonal influences or abnormal menstrual cycles when compared to using the placebo tablet.

Conditions

Hair Thinning

Keywords

Hair thinning, hair loss, alopecia, women, oral supplement

Outcome Measures

Primary Outcomes (2)

• Number of terminal hairs in the target area of the scalp.

  The first primary efficacy parameter from the phototrichogram will be the number of terminal hairs in the target area of the scalp. Terminal hair is defined as coarse hair, short or long, found on the scalp with minimum cross-sectional diameter of greater than 40 micrometers. Phototrichogram macrophotographs will be taken of the selected target area of each subject at each visit as specified under the Schedule of Procedures. Digital macrophotography will be performed using a Nikon Coolpix 4300 camera with a 3GEN Dermlite Foto37 system for scalp photography. The macrophotographs are then read by the investigator to determine the terminal hair count.

  180 days

• Number of vellus hairs in the target area of the scalp.

  The second primary efficacy parameter from the phototrichogram will be the number of vellus hairs in the target area of the scalp. Vellus hair is defined as fine, short hairs found on the scalp with maximum cross-sectional diameter of 40 micrometers. Phototrichogram macrophotographs will be taken of the selected target area of each subject at each visit as specified under the Schedule of Procedures. Digital macrophotography will be performed using a Nikon Coolpix 4300 camera with a 3GEN Dermlite Foto37 system for scalp photography. The macrophotographs are then read by the investigator to determine the vellus hair count.

  180 days

Secondary Outcomes (3)

• Dino-Lite microscopic photographs for terminal hair diameter measurements in the target area.

  180 days

• Quality of Life Questionnaire

  180 days

• Self-Assessment Questionnaire

  180 days

Study Arms (2)

New Viviscal Professional Supplement

ACTIVE COMPARATOR

New Viviscal Professional Strength Supplements. One tablet taken by mouth in the morning and one tablet in the evening with food for 180 days.

Dietary Supplement: New Viviscal Professional Supplement

Placebo Tablet

PLACEBO COMPARATOR

Placebo tablets. One tablet taken by mouth in the morning and one tablet in the evening with food for 180 days.

Dietary Supplement: Placebo tablets

Interventions

New Viviscal Professional Supplement DIETARY_SUPPLEMENT

The key ingredient is AminoMar C™ marine complex, an organic form of silica derived from Equisetum sp. (horsetail), vitamin C derived from Malpighia emarginata (acerola cherry), microcrystalline cellulose (E460), natural orange flavor, magnesium stearate, hypromellose, and glycerol. The AminoMar C ™ is an active ingredient which has been trademarked and comprises of a proprietary blend of shark powder and mollusc powder. It is derived from sustainable marine sources. Viviscal provides essential nutrients to nourish hair naturally from within. The Viviscal supplement is compared to the placebo tablet which contains no active ingredients. One tablet is taken by mouth in the morning and evening with food.

New Viviscal Professional Supplement

Placebo tablets DIETARY_SUPPLEMENT

The placebo tablet contains no active ingredients. One tablet is taken by mouth in the morning and evening with food.

Placebo Tablet

Eligibility Criteria

• Age: 21 Years - 75 Years
• Sex: female
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Females, ages 21-75 years of age.
• Clinically-determined general good health as determined by responses to the initial study assessment.
• Females with self-perceived thinning hair associated with poor diet, stress, hormone influences or abnormal menstrual cycle as determined on initial study assessment by the Investigator (This will not include patients with medically diagnosed telogen effluvium).
• Females willing to maintain their normal hair shampooing frequency.
• Females willing to add the provided oral supplement to their current daily routine.
• Females willing to not substantially change their current diet, medications, or exercise routines for the duration of the study. If a subject receives physician guidance during the study to change diet, medications, or exercise routine, the subject will need to notify the clinic as soon as possible.
• Females willing to undergo a brief physical exam to include height, weight, blood pressure, pulse, general physical findings and a scalp exam. The physical exam will occur at Visits 1, 2 and 3.
• Females with Fitzpatrick I-IV photo skin types.
• Willingness to have digital photography of the target area and scalp for hair counts at Visits 1, 2 and 3.
• Willingness to have ten (10) terminal hairs from the target area cut at the base of the scalp for microscopic hair measurements at Visits 1, 2, and 3.
• Willingness to maintain a consistent hair cut and hair color throughout the 6 month study period and to come to visits with clean (shampoo done in the morning prior to visit) and dry hair.
• Willingness of subjects who have color treated hair to have the color treatment performed at the same time interval prior to each visit (ie. If on Visit 1 the color treatment was done one week prior then the color treatment is expected to occur at a similar interval of one week prior to Visits 2 and 3)

You may not qualify if:

• Females with a known history of intolerance or allergy to fish, seafood or acerola.
• Females with any known allergy or sensitivity to any shampoo/conditioner.
• Females who are nursing, pregnant, planning to become pregnant during the study.
• Females with known stressful incident within the last six months (ie. death in family, miscarriage)
• Females who are participating on any clinical research study at ASIRC, DeNova Research or at another research center or doctor's office.
• Females who have recently (within the last 6 months) started the use of hormones for birth control or hormone replacement therapy (HRT). Women currently using hormones for birth control or HRT must have been on a stable dose (6 months or longer) in order to be eligible for the study.
• Females currently using the HairMax light treatment or other light therapy to treat thinning hair.
• Females who have regularly used Rogaine (Minoxidil) within the last 3 months.
• Females who have used prescription drugs known to affect the hair growth cycle within the last 6 months (e.g., hormone-based birth control for less than 6 months, cyproterone acetate, aldactone/spironolactone, Finasteride or any 5-alpha-reductase inhibitor).
• Females suffering from other hair loss disorders, such as alopecia areata, scarring alopecia, androgenetic alopecia and telogen effluvium as determined on initial study assessment by the Investigator.
• Individuals with self-reported uncontrolled diseases (i.e. diabetes, hypertension, hyperthyroidism, hypothyroidism, etc.). Medical conditions that are under control with or without treatment will be considered on an individual basis by the Investigators.
• Females with self-reported active hepatitis, immune deficiency, HIV or autoimmune disease.
• Females having a known active dermatologic condition which, in the opinion of the examining Investigators, might place the subject at a greater risk or interfere with clinical evaluations (e.g., seborrheic dermatitis, psoriasis, atopic dermatitis, advanced skin cancer, etc.).

Sponsors & Collaborators

• Ablon Skin Institute Research Center: lead
• Irish Response t/a Lifes2good: collaborator
• DeNova Research: collaborator

MeSH Terms

Conditions

Alopecia

Condition Hierarchy (Ancestors)

Hypotrichosis; Hair Diseases; Skin Diseases; Skin and Connective Tissue Diseases; Pathological Conditions, Anatomical; Pathological Conditions, Signs and Symptoms

Study Officials

• Glynis Ablon, MD, FAAD

  Director Ablon Skin Institute Research Center

  PRINCIPAL INVESTIGATOR

• Steven Dayan, MD, FACS

  Director DeNova Research

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 24, 2014
• First Posted: November 26, 2014
• Study Start: February 1, 2013
• Primary Completion: February 1, 2014
• Study Completion: February 1, 2014
• Last Updated: November 26, 2014

Record last verified: 2014-11